The purpose of CLCT-006, a multi-center open-label study, is to evaluate the safety of CL-108 (hydrocodone 7.5 mg/APAP 325 mg, promethazine 12.5 mg) for the treatment of moderate to severe acute pain (flare) associated with osteoarthritis of the knee or hip under actual conditions of use.~The study will also endeavor to determine~the physicians' global evaluation of CL-108 as a treatment for moderate to severe acute pain associated with osteoarthritis of the knee or hip~the patients' global impression of change in pain after treatment of moderate to severe acute pain associated with osteoarthritis of the knee or hip~any change in the patient's quality of life after treatment of moderate to severe acute pain associated with osteoarthritis of the knee or hip~the percentage change in pain intensity after treatment of moderate to severe acute pain associated with osteoarthritis of the knee or hip
The purpose of CLCT-006, a multi-center open-label study, is to evaluate the safety of CL-108 (hydrocodone 7.5 mg/APAP 325 mg, promethazine 12.5 mg) for the treatment of moderate to severe acute pain (flare) associated with osteoarthritis of the knee or hip under actual conditions of use.